Items where authors include "Small, B."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Sidhu, J.K., Siggins, M.K. orcid.org/0000-0003-2504-6518, Liew, F. orcid.org/0000-0002-8736-9198 et al. (400 more authors) (2024) Delayed mucosal antiviral responses despite robust peripheral inflammation in fatal COVID-19. The Journal of Infectious Diseases, 230 (1). e17-e29. ISSN 0022-1899

Liew, F., Efstathiou, C. orcid.org/0000-0001-6125-8126, Fontanella, S. et al. (1457 more authors) (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25 (4). pp. 607-621. ISSN 1529-2908

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Michael, B.D. orcid.org/0000-0002-8693-8926, Dunai, C. orcid.org/0000-0001-5799-2387, Needham, E.J. orcid.org/0000-0001-7042-7462 et al. (559 more authors) (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14 (1). 8487. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Goldswain, H., Dong, X., Penrice-Randal, R. et al. (405 more authors) (2023) The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection. Genome Biology, 24 (1). 47. ISSN 1474-7596

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Liew, F. orcid.org/0000-0002-8736-9198, Talwar, S., Cross, A. et al. (1439 more authors) (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87. 104402. ISSN 2352-3964